纖維蛋白原β(FGB)多克隆抗體
Polyclonal Antibody to Fibrinogen Beta Chain (FGB)
FG-B; Fibrinopeptide B; Fibrinogen Beta
- 編號PAB215Ra01
- 物種Rattus norvegicus (Rat，大鼠) 相同的名稱，不同的物種。
- 來源多抗制備
- 宿主兔
- 效價-
- Ig類型 IgG
- 純化方式抗原特異性親和純化
- 標記物無標記物
- 免疫原 RPB215Ra01-纖維蛋白原β(FGB)重組蛋白
- 緩沖液成份磷酸鹽緩沖液（pH7.4, 含有 0.01% SKL, 1mM DTT, 5% Trehalose和Proclin300.）
- 性狀液體
- 濃度500μg/mL
- 且適物種Homo sapiens (Human，人)
- 應(yīng)用WB; IHC; ICC; IP.
如果抗體需用于流式細胞術(shù)，請參見流式抗體。 - 下載 英文說明書 中文說明書
- 規(guī)格 20μl100μl 200μl 1ml 10ml
- 價格 ¥ 652 ¥ 1520 ¥ 2172 ¥ 5430 ¥ 21720
- 欲了解實際交易價格和更多情況，請與當(dāng)?shù)亟?jīng)銷商聯(lián)系!
-
產(chǎn)品包裝(模擬)
-
產(chǎn)品包裝(模擬)
-
DAB staining on IHC-P; Samples: Rat Kidney Tissue; Primary Ab: 20μg/ml Rabbit Anti-Rat FGb Antibody Second Ab: 2μg/mL?HRP-Linked Caprine Anti-Rabbit IgG Polyclonal Antibody (Catalog: SAA544Rb19)
-
DAB staining on IHC-P;
Sample: Rat Liver Tissue
Primary Ab: 20μg/ml Rabbit Anti-Rat FGB Antibody
Control: Used PBS instead of primary antibody
Second Ab: 2μg/ml HRP-Linked Caprine Anti-Rabbit IgG Polyclonal Antibody
(Catalog: SAA544Rb19) -
DAB staining on IHC-P;
Samples: Rat Liver Tissue;
Primary Ab: 20μg/ml Rabbit Anti-Rat FGb Antibody
Second Ab: 2μg/mL?HRP-Linked Caprine Anti-Rabbit IgG Polyclonal Antibody
(Catalog: SAA544Rb19) -
DAB staining on IHC-P;
Sample: Rat Spleen Tissue;
Primary Ab: 20ug/ml Rabbit Anti-Rat FGB Antibody
Second Ab: 2μg/mL?HRP-Linked Caprine Anti-Rabbit IgG Polyclonal Antibody
(Catalog: SAA544Rb19) -
DAB staining on IHC-P;
Sample: Rat Kidney Tissue
Primary Ab: 20μg/ml Rabbit Anti-Rat FGB Antibody
Control: Used PBS instead of primary antibody
Second Ab: 2μg/ml HRP-Linked Caprine Anti-Rabbit IgG Polyclonal Antibody
(Catalog: SAA544Rb19) -
DAB staining on IHC-P;
Sample: Rat Spleen Tissue
Primary Ab: 20μg/ml Rabbit Anti-Rat FGB Antibody
Control: Used PBS instead of primary antibody
Second Ab: 2μg/ml HRP-Linked Caprine Anti-Rabbit IgG Polyclonal Antibody
(Catalog: SAA544Rb19)
-
WB圖
-
Western Blot; Sample: Rat Liver lysate;
Primary Ab: 1μg/ml Rabbit Anti-Rat FGb Antibody
Second Ab: 0.2μg/mL?HRP-Linked Caprine Anti-Rabbit IgG Polyclonal Antibody
(Catalog: SAA544Rb19) -
Western Blot; Sample: Lane1: Rat Serum; Lane2: Rat Mammary gland lysate; Lane3: Rat Spleen lysate
Primary Ab: 0.02μg/ml Rabbit Anti-Rat FGB Antibody
Second Ab: 0.2μg/mL HRP-Linked Caprine Anti-Rabbit IgG Polyclonal Antibody
(Catalog: SAA544Rb19) -
Western Blot; Sample: Human Hela cell lysate;
Primary Ab: 1μg/ml Rabbit Anti-Rat FGb Antibody
Second Ab: 0.2μg/mL?HRP-Linked Caprine Anti-Rabbit IgG Polyclonal Antibody
(Catalog: SAA544Rb19)
-
通過ISO 9001、ISO 13485質(zhì)量體系認證
特異性
該抗體是針對FGB的兔多克隆抗體。在免疫組織化學(xué)染色和免疫印跡實驗中能識別FGB。
用法
免疫印跡：0.2-2μg/mL;1:250-2500
免疫組織化學(xué)：5-20μg/mL;1:25-100
免疫細胞化學(xué)：5-20μg/mL;1:25-100
最佳稀釋倍數(shù)最終由用戶決定。
儲存
經(jīng)常使用則4°C保存。-20°C保存不超過兩年。避免反復(fù)凍融。
穩(wěn)定性
熱穩(wěn)定性以損失率顯示。損失率是由加速降解試驗決定，具體方法如下：在37°C孵育48小時，沒有顯著的降解或者沉淀產(chǎn)生。保質(zhì)期內(nèi)，在適當(dāng)?shù)臈l件下存儲，損失率低于5%。
贈品
增值服務(wù)
相關(guān)產(chǎn)品
| 編號 | 適用物種：Rattus norvegicus (Rat，大鼠) | 應(yīng)用(僅供研究使用，不用于臨床診斷！) |
| RPB215Ra01 | 纖維蛋白原β(FGB)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| RPB215Ra02 | 纖維蛋白原β(FGB)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| PAB215Ra02 | 纖維蛋白原β(FGB)多克隆抗體 | WB; IHC; ICC; IP. |
| PAB215Ra01 | 纖維蛋白原β(FGB)多克隆抗體 | WB; IHC; ICC; IP. |
| LAB215Ra71 | 纖維蛋白原β(FGB)多克隆抗體(生物素標記) | WB; IHC; ICC. |
| LAB215Ra81 | 纖維蛋白原β(FGB)多克隆抗體(異硫氰酸熒光素標記) | WB; IHC; ICC; IF. |
| MAB215Ra21 | 纖維蛋白原β(FGB)單克隆抗體 | WB; IHC; ICC; IP. |
| SEB215Ra | 纖維蛋白原β(FGB)檢測試劑盒(酶聯(lián)免疫吸附試驗法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| LMB215Ra | 纖維蛋白原β(FGB)等多因子檢測試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |
| KSB215Ra01 | 纖維蛋白原β(FGB)檢測試劑盒DIY材料(酶聯(lián)免疫吸附試驗法) | 自己動手制作ELISA試劑盒的主要材料 |
參考文獻
| 雜志 | 參考文獻 |
| United States Patent Application | Compositions and Methods for Diagnosing Lung Cancer [y2016:0077095.html] |
| Microbial Pathogenesis | Crystal structure of GAPDH of Streptococcus agalactiae and characterization of its interaction with extracellular matrix molecules [Pubmed: 30553015] |
| GLYCOCONJUGATE JOURNAL | Nattokinase-heparin exhibits beneficial efficacy and safety—an optimal strategy for CKD patients on hemodialysis [Pubmed: 30788657] |
留言咨詢
